AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. (ANTX) priced its initial public offering on Mar 28, 2022 at $15.00 per share, within its $14.00–$16.00 range, raising $69M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $281.1M. TD Cowen was lead-left underwriter, joined by Leerink Partners, Evercore ISI and Oppenheimer. Cooley advised the company and Davis Polk advised the underwriters.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases. Its initial candidate, epetraborole, is a once-daily oral drug for chronic non-tuberculous mycobacterial lung disease.

Status

IPO

Ticker

ANTX

Exchange

Nasdaq Global Select

Priced

Mar 28, 2022

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$69M

Market cap at IPO price

$281.1M

First filed

Mar 4, 2022

Underwriters

TD Cowen, Leerink Partners, Evercore ISI and Oppenheimer

Company counsel

Cooley

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.